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S100A8 & S100A9: Alarmin 
mediated inflammation in 
tendinopathy
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Alarmins S100A8 and S100A9 are endogenous molecules released in response to environmental 
triggers and cellular damage. They are constitutively expressed in immune cells such as monocytes 
and neutrophils and their expression is upregulated under inflammatory conditions. The molecular 
mechanisms that regulate inflammatory pathways in tendinopathy are largely unknown therefore 
identifying early immune effectors is essential to understanding the pathology. Based on our previous 
investigations highlighting tendinopathy as an alarmin mediated pathology we sought evidence of 
S100A8 & A9 expression in a human model of tendinopathy and thereafter, to explore mechanisms 
whereby S100 proteins may regulate release of inflammatory mediators and matrix synthesis in human 
tenocytes. Immunohistochemistry and quantitative RT-PCR showed S100A8 & A9 expression was 
significantly upregulated in tendinopathic tissue compared with control. Furthermore, treating primary 
human tenocytes with exogenous S100A8 & A9 significantly increased protein release of IL-6, IL-8, 
CCL2, CCL20 and CXCL10; however, no alterations in genes associated with matrix remodelling were 
observed at a transcript level. We propose S100A8 & A9 participate in early pathology by modulating 
the stromal microenvironment and influencing the inflammatory profile observed in tendinopathy. 
S100A8 and S100A9 may participate in a positive feedback mechanism involving enhanced leukocyte 
recruitment and release of pro-inflammatory cytokines from tenocytes that perpetuates the 
inflammatory response within the tendon in the early stages of disease.
Overuse injuries of the tendon—encompassed by the term ‘tendinopathy’—represent a largely underestimated 
group of musculoskeletal disorders associated with chronic inflammation and dysregulated tissue repair1. 
Tendinopathies account for 30–50% of all sporting injuries and a high proportion of rheumatological and ortho-
paedic referrals from primary care physicians2. Despite historical disagreement between ‘inflammation’ vs ‘degen-
eration’ hypotheses it is now widely accepted that inflammatory mechanisms elicited by persistent mechanical 
injury at a microscopic level disturb the intricate homeostatic balance that exists between stromal and immune 
cell compartments within the tendon during the initial stages of disease3,4.
Expression of inflammatory mediators and associated immune cell infiltration is most pronounced in the early 
stages of tendinopathy5. Several experimental models have implicated cytokines as early immune effectors in 
stromal pathologies and essential mediators of tendon repair. Expression of cytokines and chemokines including 
IL-1, IL-33, IL-10, CCL2 and CXCL12 have been demonstrated in tenocytes and blockade of tumour necrosis 
factor alpha (TNF-α) was shown to improve the mechanical strength of tendon-bone healing in a rat rotator cuff 
repair model6–9. Conversely, surgically injured tendons of IL-6 deficient mice show reduced healing and inferior 
mechanical properties compared to normal injured controls10. In a rat model of Achilles tendon injury increased 
infiltration and accumulation of immune cells including neutrophils and macrophages was observed between 1 
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and 28 days post injury11. Subsequent human studies have identified distinct populations of myeloid monocytes 
and macrophages in both early and late tendinopathy5,12.
Monocytes recruited to areas of damage enter tissue in response to activation of chemokine pathways such as 
the CCL2/CCR2 axis13. In addition to monocytes, the myeloid compartment within the tendon may also include 
mature tissue macrophages that are programmed to respond to chemotactic factors following injury and assist 
in the initial inflammatory response. Current evidence suggests that immune cell infiltration and inflammatory 
mediators play diverse roles in the initiation and maintenance of tissue repair14. In the context of tendinopathy 
an initial inflammatory response promotes beneficial healing; however, sustained inflammatory conditions may 
eventually lead to dysregulated matrix remodelling.
Mobilization of immune cells within the tendon matrix is likely precipitated by microenvironmental changes 
that occur in response to injury15. Alarmins, also referred to as damage associated molecular patterns (DAMPS), 
are endogenous molecules rapidly released into the extracellular milieu following tissue damage16. S100A8 and 
S100A9, also known as myeloid related protein 8 (MRP8) and MRP14, are low molecular weight calcium binding 
proteins constitutively expressed by cells of myeloid origin17. Under pathological conditions they are induced in 
other cell types in response to environmental triggers. Acting as alarmins they are released passively by necrotic 
cells or by active secretion from activated immune cells18. Extracellular S100A8 and S100A9 bind pattern recog-
nition receptors (PRRs) including Toll-like receptors (TLRs) and receptor for advanced glycation end products 
(RAGE) to activate the innate immune system and mediate inflammation by influencing monocyte and mac-
rophage behavior19.
Both S100A8 and S100A9 are chemotactic for monocytes and have been implicated in myeloid cell matura-
tion where their expression directly correlates with state of differentiation20,21. Moreover, they may exert both 
pro and anti-inflammatory effects by manipulating the cytokine profile of cells through PRR binding18. S100A8 
and S100A9 are considered biomarkers of disease activity in chronic inflammatory pathologies associated with 
impaired matrix remodeling such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and cystic 
fibrosis22. In addition, gene expression studies have documented the presence of S100 proteins in tendinopathy23. 
Recent investigations have established tendinopathy as an alarmin-mediated pathology8,9 thus we sought to char-
acterize the expression of S100A8 and S100A9 in human tendinopathy and explore their biological significance 
in the context of inflammation and matrix regulation.
Results
S100A8 and S100A9 expression is increased in tendinopathy. S100A8 mRNA expression is signif-
icantly upregulated in early tendinopathy compared with control (p < 0.05) (Fig. 1A). S100A9 expression was 
more profoundly increased in both intact (p < 0.001) and torn tendon biopsies (p < 0.01) compared with control 
(Fig. 1B). We observed greatest significant upregulation of S100A8 and S100A9 in early tendinopathy and a rela-
tive absence of S100A8 mRNA expression in late tendinopathy suggesting these alarmins are key regulators in the 
early stage of disease. We next noted significantly greater protein expression of the alarmin molecules S100A8 and 
S100A9 in the early tendinopathy group compared with the control group (p < 0.05) (Fig. 1B). Both S100 proteins 
appeared not be localised around the stroma and sub analysis using back-to-back staining with the macrophage 
marker CD68 revealed that both S100A8 and S100A9 were localised to macrophage cells (Supplementary Fig. 1). 
Semi quantitative analysis again suggested that S100A9 (9% early tendinopathy, 5% late tendinopathy, % of cells 
stained positive) was more frequently expressed that S100A8 (4% early tendinopathy, 1% late tendinopathy, % of 
cells stained positive) in tissue biospies.
There were no significant correlations between S100A8 & A9 expression and the mean duration of symp-
toms, patient age or number of steroid injections (data not shown). Late tendinopathy samples exhibited marked 
degeneration, mucoid change and frank chondroid metaplasia (grade 4), whereas matched subscapularis tendon 
biopsies had grade 2–3 changes indicative of early tendinopathy. All control samples were classified as grade 1 
consistent with normal fibrotendinous tissue with large distinct collagen fibrils.
Mechanical injury stimulates release of CCL2 in vitro. Given that alarmins are rapidly released into 
the extracellular compartment following tissue damage we sought to confirm the mechanism of release of S100A8 
and S100A9 using an in vitro model of microtrauma and explore the potential inflammatory reaction of tenocytes 
after injury. Scratched tenocytes exhibit significantly increased release of CCL2 versus control (Fig. 2A, p < 0.01); 
however, we did not detect any induction of either CCL20 or CXCL10 release following injury indicating CCL2 
release from tenocytes is the primary mechanism of immune cell mobilization following tendon injury.
As CCL2 is a known chemokine for monocyte recruitment we hypothesised that these cells are recruited 
post-injury within the tendon. To simulate the stromal environment following injury CD14+ monocytes were 
incubated with conditioned medium obtained from scratched tenocytes. We observed a significant increase in 
S100A8 release compared with unscratched control (p < 0.05) (Fig. 2B). Although not statistically significant, 
S100A9 release following incubation with tenocyte conditioned medium was also greater than unscratched and 
comparable to values observed with LPS stimulation (Fig. 2C).
S100A8 and S100A9 do not directly alter matrix proteins in vitro. Previous investigations have 
shown that alarmins differentially regulate collagen synthesis and expression of matrix proteins in tendinopathy8,9 
thus we sought to assess the effect of extracellular S100A8 and S100A9 on matrix regulation in primary human 
tenocytes. Neither S100A8 or S100A9 had any significant effect on Col1a1, Col3a1, Decorin or Tenascin C gene 
expression following 24 hours stimulation relative to controls (Fig. 3A–F).
To assess the effect of S100A8 & A9 on protease release in tenocytes we performed an array that allows simul-
taneous detection of 35 proteases. We found a marked increase in MMP3 expression between control vs S100A9 
(Fig. S2). This was validated at protein level where a significant increase in MMP3 release from tenocytes was 
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Figure 1. S100A8 and S100A9 expression is increased in tendinopathy. (A) Relative mRNA expression  
(2-ΔCT) of S100A8 & S100A9 in control (hamstring tendon, n = 7), early tendinopathy (intact subscapularis 
biopsy, n = 14) and late tendinopathy (torn supraspinatus tendon, n = 12). Data represent mean ± SEM relative 
to housekeeping gene GAPDH (mean of duplicate analysis). *p < 0.05, **p < 0.01, ***p < 0.001 (Kruskal-
Wallis test) versus control. (B) Immunostaining of S100A8 and S100A9 in early tendinopathy (subsapularis 
biopsy) at 10x and 40x magnification. (C) Graphs illustrate modified Bonar scoring and percentage of cells 
stained positive for samples of human tendon biopsies for expression of S100A8 and A9 with mean and SEM 
shown. n = 10 for control tendon, n = 10 for early and late tendinopathy. Modified Bonar scoring system depicts 
mean score per sample based on five high-power fields. 0 = no staining, 1 = < 10%, 2 = 10%–20%, 3 = > 20% 
positive staining of cells per high-power field. *p < 0.05, **p < 0.01 (ANOVA) versus control biopsies. 
+p < 0.05 late versus early tendinopathy.
www.nature.com/scientificreports/
4Scientific RepoRts |          (2019) 9:1463  | https://doi.org/10.1038/s41598-018-37684-3
observed upon stimulation with S100A9 (Fig. S2A). Additionally, we found upregulation of MMP3 transcript in 
response to both S100A8 and S100A9 stimulation (Fig. 3G), however no increase in TIMPs 1 or 2 were observed. 
Furthermore, no effect was observed on collagen I protein release from tenocytes in response to S100 stimulation 
(Supplementary Fig. S3).
S100A8 and S100A9 induce secretion of inflammatory mediators from human tenocytes. We 
next explored the extent to which S100 proteins may influence the inflammatory microenvironment within 
the tendon post-injury. Recombinant S100A9 at a concentration of 1ug/ml significantly increased release of 
IL-6 (p < 0.01), IL-8 (p < 0.05) and CCL20 (p < 0.01) from tenocytes (Fig. 4). Furthermore, S100A9 stimula-
tion induced a 40 fold increase in CXCL10 expression compared to control (not detected). S100A8 stimulation 
displayed the same trend of significant IL-8 (p < 0.05) and CCL2 (p < 0.001) release from tenocytes; however, 
increases in IL-6 and CCL20 release were not significant following 24 hours’ stimulation. Taken together, these 
data suggest S100A8 and S100A9 play a role in the activation of resident tenocytes and initiate a cascade of 
inflammatory processes.
Discussion
Our study has established the presence of S100A8 and S100A9 in a human model of tendinopathy, most nota-
bly in the early stages of disease. Coupled with confirmation of passive release of CCL2 in response to acute 
injury our data supports the concept of S100A8 & A9 acting as functional tissue alarmins in tendinopathy by 
promoting immune cell recruitment. We have identified that S100A8 & A9 play an important immunomodu-
latory role in tendinopathy through activation of the innate immune system and manipulation of the stromal 
microenvironment.
Increasingly, alarmins are becoming recognized as key regulators in musculoskeletal pathologies16,24. S100A8 
and S100A9 are considered surrogate markers of disease activity in RA where serum concentrations directly 
reflect levels of active inflammation25,26. In addition, S100A8 & A9 promote recruitment of inflammatory mono-
cytes to the synovium in a murine model of osteoarthritis and blockade of S100 signalling ameliorates inflam-
matory processes27. Previous investigations in human models of tendinopathy have consistently established the 
Figure 2. Damage induces release of CCL2 from tenocytes. (A) CCL2 release measured by ELISA in 
supernatants collected from tenocytes scratched and incubated for 24 hours post injury compared to 
unscratched control. (B) S100A8 and S100A9 concentration in supernatants from CD14+ monocytes (isolated 
from buffy coats) cultured in conditioned medium from tenocyte scratch assay for 24 hours. ‘nd’ indicates not 
detected. All data represent mean ± SEM. n = 3 donors *p < 0.05, **p < 0.01 versus control (Student’s t-test).
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presence of alarmins in diseased tendon and revealed functional roles in vitro8,9,28. Most recently we have demon-
strated the alarmin HMGB1 regulates expression of inflammatory cytokines and matrix changes in tenocytes in 
a TLR4 dependent manner9. Observations taken from the present study indicate S100A8 and S100A9 regulate 
expression of inflammatory mediators in vitro which corroborates previous findings and suggests S100A8 & A9 
Figure 3. S100A8 and S100A9 do not directly alter matrix proteins in vitro (A) Col1a1, (B) Col3a1, (C) 
Decorin, (D) Tenascin C, (E) TIMP1, (F) TIMP2 and (G) MMP3 mRNA expression in tenocytes stimulated 
1 µg/ml recombinant S100A8, 1 µg/ml recombinant S100A9 or 1 ng/ml LPS for 24 hours was determined by real 
time PCR. Data represent mean ± SEM of duplicate samples expressed as relative fold change normalised to 
control (unstimulated) samples, n = 3.
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are likely acting through DAMP receptors to influence downstream transcription and release of CCL2, CCL20, 
CXCL10, IL-6 and IL-8.
Hallmark features of tendinopathy include dysregulated collagen synthesis with a detrimental transition from 
type 1 to an inherently weaker type 329. In addition, ECM turnover is regulated by non-structural matricellular 
proteins such as decorin and tenascin C that are thought to be upregulated under inflammatory conditions and 
in response to mechanical strain30. Interestingly, the present study did not find any changes in collagen, decorin 
or tenascin C in tenocytes in response to S100A8 & A9 stimulation. This may reflect differences in endogenous 
activity of various DAMPs. In addition to passive secretion from necrotic cells, under pathological conditions 
intracellular alarmins reserve the potential to be secreted from activated immune cells. In contrast to the relatively 
slow translocation dependent secretion of nuclear HMGB131, active secretion of S100A8 & A9 from monocytes 
is rapid and energy dependent32 suggesting they are inherently programmed to facilitate early inflammatory 
responses rather than directly alter extracellular matrix production.
Figure 4. S100A8 and S100A9 induce cytokine and chemokine release from human tenocytes Tenocytes 
stimulated with 1ug/ml S100A8, 1ug/ml S100A9 or 10 ng/ml IL-1β. Concentrations of IL-6 (A) IL-8 (B) CCL2 
(C) CCL20 (D) or CXCL10 (E) in cell culture supernatants measured following 24 hours stimulation. Values 
expressed as pg/ml. All data represent mean ± SEM, n = 3, *p < 0.05, **p < 0.01, ***p < 0.001 compared to 
control (unstimulated) samples (Student’s t-test).
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Protease screening confirmed induction of MMP3 in response to S100 stimulation. MMPs are generally con-
sidered to be fibrinolytic modulators of extracellular matrix turnover and have been associated with ongoing 
tissue damage and development of chronic disease33,37. Evidence suggests they are also involved in regulation 
of inflammatory processes including cytokine processing and activation34,35, and leukocyte migration36. We did 
not observe any changes in other matrix proteins or tissue inhibitors of metalloproteinases (TIMP1 and TIMP2) 
therefore, in the context of tendinopathy, MMP3 may regulate inflammation in addition to influencing matrix 
remodelling.
Recent evidence has revealed that stromal fibroblast activation markers are persistently upregulated in dis-
eased tendon38. In response to recurrent injurious or inflammatory stimuli stromal cells are subject to pheno-
typic transformations that alter their functional properties; such adaptations reflect the activation state of the cell 
population. Typically, stromal cell activation is characterised by rapid induction of cytokines, chemokines and 
extracellular matrix components39. We observed an induction of CCL2, CCL20, CXCL10, IL-6 and IL-8 release 
from tenocytes in response to S100A8 & A9 stimulation suggesting their primary action may be activation of the 
resident tenocyte population. This, in turn, will promote immune cell recruitment and influence the nature of 
stromal microenvironmental cues.
The CCL2/CCR2 axis is primarily associated with the initial recruitment of classical inflammatory monocytes 
to sites of inflammation or tissue damage40,41. Within the tendon a portion of the recruited monocytes may con-
tinue development into macrophages following egress into the stromal microenvironment. It is thought classical 
monocytes recruited by CCL2 are programmed to differentiate more readily into inflammatory macrophages and 
may promote excessive inflammation42. Conversely, synergistic activities of IL-6 and CCL2 have been shown to 
induce alternative activation of myeloid monocytes43. As such, the recruitment and development of monocytes 
and macrophages is highly niche specific and undifferentiated monocytes/macrophages retain the potential to 
differentiate according to their environment. Given the complex nature of the stromal microenvironment is it 
likely that both ‘classical’ inflammatory macrophages and ‘alternatively activated’ macrophages exist as a dichot-
omy that drives a state of chronic inflammation.
Based on our observations using a previously explored in vitro injury model we propose that acute injury 
induces CCL2 mediated monocyte recruitment44. Here, soluble factors or biologically active ECM fragments 
induce subsequent release of S100A8 and S100A9 from monocytes that will, in turn, bind receptors on the teno-
cyte surface and stimulate release of further inflammatory factors (Fig. 5). Within the tendon matrix monocytes 
continue development to mature macrophages and differentiate according to environmental cues. Histologically 
the presence of mononuclear cells is associated with a state of chronic inflammation45. Excessive immune cell 
infiltration and the presence of macrophages may contribute to persistence of inflammation and promote 
immune cell-matrix crosstalk that drives inflammatory healing characterised by aberrant and inferior matrix 
repair. It may be postulated in the context of this study that CCL2, CCL20 and CXCL10 mediate initial inflam-
matory monocyte recruitment while IL-6 and IL-8 participate as potent inflammatory factors in the acute phase 
response. This will subsequently act to promote a transitory state towards established chronic inflammation. In 
Figure 5. S100A8 and S100A9 promote immune cell recruitment and development in tendinopathy 
Proposed mechanism whereby damage induces release of CCL2 from tenocytes recruiting monocytes to 
the site of injury. Soluble factors stimulate release of S100A8 and S100A9 from monocytes recruited to the 
tendon matrix. S100A8 and S100A9 bind receptors on the tenocyte surface to induce release of cytokines and 
chemokines promoting further recruitment and development of immune cells. Formation of an inflammatory 
microenvironment facilitates immune cell-matrix cross talk and promotes a state of chronic inflammation.
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addition to monocyte recruitment these chemokines are capable of recruiting T cells, mast cells and natural killer 
cells that will likely contribute to the development of a complex and dynamic inflammatory milieu.
A recent study detailing the expression of alarmins in the fibrotic disorder adhesive capsulitis demonstrated 
S100A8/S100A9 expression is localised to immune cells; specifically, CD68+ macrophages46. Our data describing 
S100A8 & A9 release from monocytes highlights the importance of activated immune cells as a source of alarmins 
in diseased tendon. Under inflammatory conditions S100A8 and S100A9 are known to regulate positive feedback 
mechanisms thus it is plausible tenocytes and activated monocytes/macrophages mutually amplify levels of extra-
cellular alarmins and promote phagocyte recruitment47,48. Furthermore, S100A8/S100A9 are involved in myeloid 
cell differentiation and induce secretion of pro-inflammatory cytokines including TNF-α and IL-1ß from mono-
cytes49; it is likely these mediators will also act to exaggerate and sustain inflammatory conditions.
There are limitations inherent in our study. Age-related changes within the tendon samples could contribute to 
the degenerative picture and alarmin expression seen in the matched subscapularis tendons. However, the lack of 
degenerative change on MRI and arthroscopic examinations suggests that the differences are truly at the cellular 
level as suggested by our work. Subscapularis tendon is functionally and organizationally distinct from supraspi-
natus thus responds to mechanical loading in a different manner that may alter its cellular profile. Control sam-
ples from subscapularis undergoing stabilisation may not be truly ‘normal’ controls but are currently the best 
available control tendon sample and this is reflected by a Bonar score of 1. It is reassuring, however, that we found 
the same inflammatory cell subtypes in matched subscapularis tissue indicating that the inflammatory response 
may be uniform within joints subjected to tendon degeneration. In addition, having subscapularis samples from 
the same patient eliminates bias that may result from variation between individuals and has been previously 
shown to be useful method in sampling of tissues. We also point out that, while our human tissue biopsies show 
the presence of S100A8 & A9 at mRNA and protein level, the majority of our mechanistic work utilises an early 
disease in vitro culture system. Further mechanistic investigation in an in vivo tendon model and late disease in 
vitro cultures would more likely address the hierarchal role of S100 molecules in tendon pathogenesis.
Conclusions
Our data confirms the presence of S100A8 and S100A9 in tendinopathy and suggests they actively contribute 
to pathological proceedings in the early stages of disease. We propose that by modulating the stromal microen-
vironment S100A8 and S100A9 promote recruitment of inflammatory cells to the site of injury and support a 
detrimental transition from acute to chronic inflammation. Selectively targeting DAMP signalling in early disease 
provides scope for novel translational strategies in the management of tendon disorders.
Materials and Methods
Human model of tendinopathy. All procedures and protocols were approved by the Ethics Committee 
under approval numbers Central Network, South East Health (HREC/96/55, HREC/14/130) and West of 
Scotland REC (REC14/WS/1035) with informed consent obtained and carried out in accordance with stand-
ard operative procedures. For immunohistochemistry, ten supraspinatus tendon samples were collected from 
patients with rotator cuff tears undergoing shoulder surgery (Table 1). The mean age of the rotator cuff ruptured 
patients was 50 years (range, 30–62 years) —the mean tear size was 2.2 cm2 (range 1–4 cm2). Samples of the 
subscapularis tendon were also collected from the same patients. Patients were only included if there was no 
clinically detectable evidence of subscapularis tendinopathy on a preoperative MRI scan as determined by a 
musculoskeletal radiologist or macroscopic damage to the subscapularis tendon at the time of arthroscopy as 
determined by the senior author (NLM)—by these criteria they represented a preclinical cohort. In this cohort, 
all patients fulfilled the following criteria: (1) a history of shoulder pain and dysfunction, (2) no previous sur-
gery on the affected shoulder, (3) no radiographic sign of fracture of the shoulder and (4) no history of RA or 
osteoarthritis50. An independent control group was obtained comprising ten samples of subscapularis tendon 
collected from patients undergoing arthroscopic surgery for shoulder stabilisation without rotator cuff tears, no 
previous shoulder surgery, no radiographic signs of shoulder fracture, or history of RA or OA. The absence of 
rotator cuff tears was confirmed by arthroscopic examination. The mean age of the control group was 23 years 
(range, 16–28 years). For mRNA expression, fourteen (mean 49 years range, 30–65 years) early tendinopathy 
(subscapularis) samples, 12 late (mean 54 years range, 38–68 years) tendinopathy (supraspinatus) samples were 
utilised while 8 hamstring tendons (mean 23 years (range, 15–25 years) obtained at the time of routine anterior 
cruciate ligament reconstruction were employed (utilised as control due to lack of subscapularis control RNA) 
as an independent control group. Additionally, standardised patient demographics were obtained preoperatively 
and included the duration of shoulder symptoms experienced by the patient and the number of subacromial 
steroid injections.
Tear Size Control Small (<1 cm2) Medium (>1–3 cm2) Large (>3–5 cm2)
Number of cases 10 4 4 2
Mean age in years (range) 21 (16–28) 44 (30–58) 48 (46–62) 52 (42–53)
Mean duration of symptoms in months (range) 6.0 (2–12) 8.2 (2–18) 6.8 (2–16) 8.6 (5–18)
Mean number of steroid injections 0 1.8 1.1 1.7
Table 1. Patient demographics.
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Cell culture and treatments. Human tendon-derived cells were explanted form hamstring tendons of 
patients undergoing anterior ligament reconstruction. Patients were age ranged from 18–25. Hamstring tendons 
were cut into 2 mm3 pieces and placed in RPMI 1640 supplemented with 10% heat-inactivated Fetal Bovine 
Serum (FBS), 100 µg/ml penicillin, 100 µg/ml streptomycin and 2nM L-glutamine (all Thermo Fisher Scientific). 
Explants were maintained in a humidified environment at 37 °C, 5% CO2 to allow tenocytes to adhere. Medium 
was replenished every 5 days until cells were confluent. Tissue was then removed and cells were placed in fresh 
medium. Cells were passaged using trypsin-EDTA (Sigma-Aldrich). Tenocytes from the second and third passage 
were seeded two days prior to stimulation.
Normal tenocytes were seeded at 2.5 × 104/ml in 24 well culture plates and allowed to rest for 48 hours. 
Adherent tenocytes were stimulated with 1 µg/ml recombinant human S100A8 (Abcam), S100A9 (Abcam), 10 ng/
ml LPS or 10 ng/ml IL-1ß for 24 hours in complete RPMI.
Scratch assay. Normal tenocytes were seeded at 5 × 104/ml in 12 well culture plates and scratched 4 times 
across the diameter of the plate with a sterile pipette tip. Injured cells were incubated for 24 hours before harvest-
ing of supernatants44,51.
Monocyte stimulation. Buffy coats from healthy volunteers were obtained from the Scottish National 
Blood Transfusion Service (SNBTS) under the reference 10–12 (v2). Human CD14+ monocytes were obtained 
from buffy coats by density gradient separation. Peripheral blood mononuclear cells were incubated with 
CD14 microbeads (Miltenyi) and posititvely selected via magnetic separation using autoMACS Pro Separator. 
CD14 + monocytes were seeded in 24 well culture plates at a density of 2.5 × 105 per well with supernatants 
(diluted 1 in 2 with complete RPMI) obtained from the tenocyte scratch assay for 24 hours.
RNA extraction, cDNA synthesis and real time qPCR. Tendon tissue was placed in RNA later solu-
tion (Ambion) and stored at -20 °C. Tissue samples were homogenized in PureLink lysis buffer containing 1% 
2-mercaptoethanol using a Qiagen Tissue Lyser LT. Total RNA was isolated using the PureLink RNA Mini Kit 
(Thermo Fisher Scientific) according to manufacturer’s instructions.
Cells were placed in PureLink lysis buffer containing 1% 2-mercaptoethanol and RNA was extracted using 
mini columns according to the PureLink protocol.
RNA concentration and purity was determined using a spectrophotometer (Nanodrop 2000, Thermo 
Scientific). 100 ng of RNA was converted to cDNA using High Capacity cDNA reverse transcription kit (Thermo 
Fisher Scientific) according to manufacturer’s instructions. cDNA was diluted 1 in 5 using RNase free water. 
qPCR was performed using PowerUp Sybr Green Mastermix (Thermo Fisher Scientific) and 1 μl cDNA was used 
per reaction with 0.1 μM of forward and reverse primers. Each sample was run in duplicate and normalized to 
GAPDH or 18 S endogenous control. Data represents relative mRNA expression (2-ΔCT) or fold change from 
untreated cells (2-ΔΔCT).
Primers (Integrated DNA Technologies) were as follows:
GAPDH (f) 5′-TCGACAGTCAGCCGCATCTTCTTT-3′ (r) 5′-ACCAAATCCGTTGACTCCGA CCTT-3′
18S (f) 5′-GTAACCCGTTGAACCCCATT-3′ (r) 5′-CCATCCAATCGGTAGTAGCG-3′
Col1a1 (f) 5′-CAATGCTGCCCTTTCTGCTCC-3′ (r) 5′-CACTTGGGTGTTTGAGCATTG-3′
Col3a1 (f) 5′- TATCGAACACGCAAGGCTGTG-3′ (r) 5′-
GGCCAACGTCCACACCAAATT-3′
S100A8 (f) 5′-AGACCGAGACCGAGTGTCCTC-3′ (r) 5′-
TGCCACGCCCATCTTTAT-3′
S100A9 (f) 5′-TCAAAGAGCTGGTGCGAAA-3′ (r) 5′-
CAGCTGCTTGTCTGCATTTG-3′
Tenascin C (f) 5′-CTTTGGCTGGGTTGCTTGAC-3′ (r) 5′-GTGCCAGGAGACCGTACCAC-3′
Decorin (f) 5′-CGCCTCATCTGGAGGGAGCTT-3′ (r) 5′-CTTTGGCTGGGTTGCTTGAC-3′
TIMP1 (f) 5′-GTAGACGAACCGGATGTCAG -3′ (r) 5′- GAAGTCAACACCTTAT-3′
TIMP2 (f) 5′-AGGGCCTGAGAATATAGAG-3′ (r) 5′-GGCCTTTCCAATGAGARA-3′
MMP3 (f) 5′-ACCCACCTTACATACAGGATT-3′ (r) 5′-ACCCACCTTACATACAGGATTG-3′
Measurement of cytokine release by ELISA. Cell culture supernatants were collected from tenocytes 
stimulated with 1 µg/ml S100A8 & S100A9, 10 ng/ml IL-1ß for 24 hours and the concentrations of IL-6, IL-8, 
CCL2 (Thermo Fisher Scientific, range 2000-31.25 pg/ml), CCL20, CXCL10 (Biolegend, CCL20 range 160-5 pg/
ml, CXCL10 1000-15.6 pg/ml)), S100A8 and S100A9 (R & D systems, range 2000-31.25 pg/ml) were determined 
using commercially available ELISA kits. Cell culture supernatants were diluted with assay diluent to achieve 
concentrations within the specified range. Optical density was measured at 450 nm by a microplate reader.
Histology and immunohistochemistry techniques. Samples were stained with H&E and toluidine 
blue for determination of the degree of tendinopathy as assessed by a modified version of the Bonar score (Grade 
4 = marked tendinopathy, Grade 3 = advanced tendinopathy, Grade 2 = moderate degeneration, Grade 1 = mild 
degeneration, Grade 0 = normal tendon). This included the presence or absence of oedema and degeneration 
together with the degree of fibroblast cellularity and chondroid metaplasia. Thereafter, sections were stained with 
a range of primary antibodies directed against the following markers: S100A8 monoclonal antibody (Abnova 
MAB7961 Clone CF-145, UK; 2 µg/mL, 1:500 dilution), and S100A9 polyclonal antibody (Abnova PAB11470, 
UK; 2 µg/mL, 1:250 dilution).
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Endogenous peroxidase activity was quenched with 3% (v/v) H2O2, and non-specific antibody binding 
blocked with 2.5% horse serum in Tris buffered saline (TBS) solution with detergent Tween20 (TBST) buffer 
for 30 min. Antigen retrieval was performed in 0.01 M citrate buffer for 20 min in a microwave. Sections were 
incubated with primary antibody in 2.5% (w/v) horse serum/human serum/TBST at 4 °C overnight. After two 
washes, slides were incubated with Vector ImmPRESS Reagent kit as per manufacturer’s instructions for 30 min. 
The slides were washed and incubated with Vector ImmPACT DAB chromagen solution for 2 minutes followed 
by extensive washing. Finally, the sections were counterstained with haematoxylin.
Images were captured using Apple Open laboratory software. Positive (human tonsil tissue) control specimens 
were included, in addition to the surgical specimens for each individual antibody staining technique and double 
immunofluorescence staining. Omission of primary antibody and use of negative control (human OA samples) 
isotypes confirmed the specificity of staining.
We applied a scoring system based on previous methods to quantify the immunohistochemical staining. Five 
random high-power fields (×400) were evaluated by two independent assessors (NLM, JHR). In each field, the 
number of positive and negatively stained cells were counted and the percentage of positive cells calculated giving 
the following semi quantitative grading: Grade 0 = no staining, Grade 1 = <10% cells stained positive, Grade 
2 = 10–20% cells stained positive, Grade 3 = >20% cells positive.
Protease Array. Cell supernatants were evaluated for the presence and relative amounts of 35 proteases 
using the Proteome Profiler Human Protease Array Kit (R&D Systems) according to the manufacturer’s protocol. 
Equal volumes of supernatants from tenocytes stimulated 1 µg/ml recombinant human S100A8 (Abcam), S100A9 
(Abcam), 10 ng/ml IL-1ß for 24 hours were pooled from three donors and applied to the respective array mem-
brane. Samples were then mixed with a combination of biotinylated detection antibodies and incubated overnight 
at 4 °C. The membranes were then subject to a series of washes before addition of diluted solution of horserad-
ish peroxidase-conjugated streptavidin at room temperature for 30 minutes. Visualization of protease expression 
was carried out by chemiluminescence and signal intensity was quantified using an Azure c500 imaging system 
(Azure Biosystems). Relative optical densities of immunoreactive bands were determined using Image Studio Lite 
software (Li-Cor Biosciences).
Statistical analysis. All values are expressed as mean ± SEM. Statistical analysis was performed using 
Kruskal-Wallis one-way analysis of variance or Student’s t-test. Values of p = < 0.05 are considered statistically 
significant.
Ethical approval information. All procedures and protocols were approved by the Ethics Committee 
under approval numbers Central Network, South East Health (HREC/96/55, HREC/14/130) and West of 
Scotland REC (REC14/WS/1035) with informed consent obtained and carried out in accordance with standard 
operative procedures.
Data Availability
L.A.N.C. has access to all the data and data are available upon request.
References
 1. Xu, Y. & Murrell, G. A. The basic science of tendinopathy. Clinical orthopaedics and related research 466, 1528–1538 (2008).
 2. Abat, F. et al. Current trends in tendinopathy: consensus of the ESSKA basic science committee. Part I: biology, biomechanics, 
anatomy and an exercise-based approach. J Exp Orthop 4, 18 (2017).
 3. Millar, N. L., Murrell, G. A. & McInnes, I. B. Inflammatory mechanisms in tendinopathy-towards translation. Nature Reviews 
Rheumatology 13, 110–122 (2017).
 4. Dakin, S. G., Dudhia, J. & Smith, R. K. Resolving an inflammatory concept: the importance of inflammation and resolution in 
tendinopathy. Veterinary immunology and immunopathology 158, 121–127 (2014).
 5. Millar, N. L. et al. Inflammation is present in early human tendinopathy. The American journal of sports medicine 38, 2085–2091 
(2010).
 6. Gulotta, L. V., Kovacevic, D., Cordasco, F. & Rodeo, S. A. Evaluation of tumor necrosis factor α blockade on early tendon-to-bone 
healing in a rat rotator cuff repair model. Arthroscopy: the journal of arthroscopic & related surgery 27, 1351–1357 (2011).
 7. Tsuzaki, M. et al. IL-1 beta induces COX2, MMP-1, -3 and -13, ADAMTS-4, IL-1 beta and IL-6 in human tendon cells. J Orthop Res 
21, 256–264 (2003).
 8. Millar, N. L. et al. MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nature communications 6 (2015).
 9. Akbar, M. et al. Targeting danger molecules in tendinopathy: the HMGB1/TLR4 axis. RMD open 3, e000456 (2017).
 10. Lin, T. W., Cardenas, L., Glaser, D. L. & Soslowsky, L. J. Tendon healing in interleukin-4 and interleukin-6 knockout mice. Journal of 
biomechanics 39, 61–69 (2006).
 11. Marsolais, D., Cote, C. H. & Frenette, J. Neutrophils and macrophages accumulate sequentially following Achilles tendon injury. J 
Orthop Res 19, 1203–1209 (2001).
 12. Dakin, S. G. et al. Inflammation activation and resolution in human tendon disease. Science translational medicine 7, 
311ra173–311ra173 (2015).
 13. Shi, C. & Pamer, E. G. Monocyte recruitment during infection and inflammation. Nature reviews immunology 11, 762 (2011).
 14. Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A. & Locati, M. Macrophage plasticity and polarization in tissue repair and 
remodelling. The Journal of pathology 229, 176–185 (2013).
 15. Dean, B. J., Dakin, S. G., Millar, N. L. & Carr, A. J. Emerging concepts in the pathogenesis of tendinopathy. The surgeon (2017).
 16. Nefla, M., Holzinger, D., Berenbaum, F. & Jacques, C. The danger from within: alarmins in arthritis. Nature Reviews Rheumatology 
12, 669–683 (2016).
 17. Edgeworth, J., Gorman, M., Bennett, R., Freemont, P. & Hogg, N. Identification ofp8, 14 as a highly abundant heterodimeric calcium 
binding protein complex of myeloid cells. Journal of Biological Chemistry 266, 7706–7713 (1991).
 18. Donato, R. et al. Functions of S100 proteins. Current molecular medicine 13, 24–57 (2013).
 19. Foell, D., Wittkowski, H. & Roth, J. Mechanisms of disease: a ‘DAMP’ view of inflammatory arthritis. Nature clinical practice 
Rheumatology 3, 382–390 (2007).
 20. Viemann, D. et al. Myeloid-related proteins 8 and 14 induce a specific inflammatory response in human microvascular endothelial 
cells. Blood 105, 2955–2962 (2005).
www.nature.com/scientificreports/
1 1Scientific RepoRts |          (2019) 9:1463  | https://doi.org/10.1038/s41598-018-37684-3
 21. Koike, T., Harada, N., Yoshida, T. & Morikawa, M. Regulation of myeloid-specific calcium binding protein synthesis by cytosolic 
protein kinase C. The Journal of Biochemistry 112, 624–630 (1992).
 22. Foell, D., Frosch, M., Sorg, C. & Roth, J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of 
inflammation. Clinica Chimica Acta 344, 37–51 (2004).
 23. Jelinsky, S. A. et al. Regulation of gene expression in human tendinopathy. BMC musculoskeletal disorders 12, 86 (2011).
 24. Millar, N. L., Murrell, G. A. & McInnes, I. B. Alarmins in tendinopathy: unravelling new mechanisms in a common disease. 
Rheumatology (Oxford) 52, 769–779 (2013).
 25. Chen, Y.-S., Yan, W., Geczy, C. L., Brown, M. A. & Thomas, R. Serum levels of soluble receptor for advanced glycation end products 
and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in 
rheumatoid arthritis. Arthritis research & therapy 11, R39 (2009).
 26. Kang, K. Y., Woo, J.-W. & Park, S.-H. S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with 
rheumatoid arthritis. The Korean journal of internal medicine 29, 12 (2014).
 27. Sloetjes, A. et al. S100A8/A9 increases the mobilization of pro-inflammatory Ly6C high monocytes to the synovium during 
experimental osteoarthritis. Arthritis research & therapy 19, 217 (2017).
 28. Mosca, M. J. et al. Differential expression of alarmins—S100A9, IL-33, HMGB1 and HIF-1α in supraspinatus tendinopathy before 
and after treatment. BMJ Open Sport & Exercise Medicine 3, e000225 (2017).
 29. Sharma, P. & Maffulli, N. Biology of tendon injury: healing, modeling and remodeling. Journal of Musculoskeletal and Neuronal 
Interactions 6, 181 (2006).
 30. Bornstein, P. Matricellular proteins: an overview. Journal of cell communication and signaling 3, 163 (2009).
 31. Lu, B. et al. Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review. 
Expert review of clinical immunology 10, 713–727 (2014).
 32. Rammes, A. et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by 
activated monocytes via a novel, tubulin-dependent pathway. Journal of Biological Chemistry 272, 9496–9502 (1997).
 33. Page-McCaw, A., Ewald, A. J. & Werb, Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nature reviews 
Molecular cell biology 8, 221 (2007).
 34. McQuibban, G. A. et al. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine 
receptor antagonists with anti-inflammatory properties in vivo. Blood 100, 1160–1167 (2002).
 35. Schönbeck, U., Mach, F. & Libby, P. Generation of biologically active IL-1β by matrix metalloproteinases: a novel caspase-1-
independent pathway of IL-1β processing. The Journal of Immunology 161, 3340–3346 (1998).
 36. Haro, H. et al. Matrix metalloproteinase-3–dependent generation of a macrophage chemoattractant in a model of herniated disc 
resorption. The Journal of clinical investigation 105, 133–141 (2000).
 37. Manicone, A. M. & McGuire, J. K. Matrix metalloproteinases as modulators of inflammation. Seminars in cell & developmental 
biology; 2008 p. 34–41, (Elsevier; 2008).
 38. Dakin, S. G. et al. Persistent stromal fibroblast activation is present in chronic tendinopathy. Arthritis research & therapy 19, 16 
(2017).
 39. Patel, R., Filer, A., Barone, F. & Buckley, C. D. Stroma: fertile soil for inflammation. Best Practice & Research Clinical Rheumatology 
28, 565–576 (2014).
 40. Van Furth, R., Diesselhoff-den Dulk, M. M. & Mattie, H. Quantitative study on the production and kinetics of mononuclear 
phagocytes during an acute inflammatory reaction. Journal of experimental medicine 138, 1314–1330 (1973).
 41. Lu, B. et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1–deficient mice. 
Journal of Experimental Medicine 187, 601–608 (1998).
 42. Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656–661 (2010).
 43. Roca, H. et al. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-
type macrophage polarization. Journal of Biological Chemistry 284, 34342–34354 (2009).
 44. Girke, G. et al. Tenocyte activation and regulation of complement factors in response to in vitro cell injury. Molecular immunology 
60, 14–22 (2014).
 45. Gabay, C. Interleukin-6 and chronic inflammation. Arthritis research & therapy 8, S3 (2006).
 46. Cher, J. Z. B. et al. Alarmins in Frozen Shoulder: A Molecular Association Between Inflammation and Pain. Am J Sports Med, 
363546517741127 (2017).
 47. Schiopu, A. & Cotoi, O.S. S100A8 and S100A9: DAMPs at the crossroads between innate immunity, traditional risk factors, and 
cardiovascular disease. Mediators of inflammation 2013 (2013).
 48. Roth, J., Vogl, T., Sorg, C. & Sunderkötter, C. Phagocyte-specific S100 proteins: a novel group of proinflammatory molecules. Trends 
in immunology 24, 155–158 (2003).
 49. Vogl, T. et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nature 
medicine 13, 1042–1049 (2007).
 50. Scott, A., Lian, Ø., Bahr, R., Hart, D. A. & Duronio, V. VEGF expression in patellar tendinopathy: a preliminary study. Clinical 
orthopaedics and related research 466, 1598–1604 (2008).
 51. Liang, C.-C., Park, A. Y. & Guan, J.-L. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in 
vitro. Nature protocols 2, 329 (2007).
Acknowledgements
This work was funded by the Medical Research Council (MR/K501335/1 and MR/R020515/1), Arthritis Research 
UK (21346) and Tenovus Scotland.
Author Contributions
L.A.N.C., M.A., E.G.M., K.P., H.M.C., M.M. and N.L.M. conceived and designed the experiments. L.A.N.C., 
M.A., E.G.M., K.P., H.M.C., M.M. and J.H.R. performed experiments. I.B.M., W.J.L., B.P.R., M.M., S.J.S. and M.C. 
provided expert advice. All authors analysed the data. L.A.N.C. and N.L.M. wrote the paper.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-37684-3.
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 2Scientific RepoRts |          (2019) 9:1463  | https://doi.org/10.1038/s41598-018-37684-3
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
